Stockwinners Market Radar for August 11, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:34 EDT Google collaborates with USGS, Cal OES to send earthquake alerts - Google said in a blog post that it is collaborating with the United States Geological Survey and California Governor's Office of Emergency Services to send earthquake alerts, powered by ShakeAlert, directly to Android devices in California. Developed by the nation's leading seismologists, the ShakeAlert system uses signals from more than 700 seismometers installed across the state by USGS, Cal OES, University of California Berkeley, and the California Institute of Technology, the company said. Reference Link

18:25 EDT ServiceNow's Chadwick sells 3,601 common shares - In a regulatory filing, ServiceNow director Jonathan Chadwick disclosed the sale of 3,601 common shares of the company on August 10 at a price of $430.44 per share.

17:56 EDT TTEC Holdings director sells 20K shares of common stock - In a regulatory filing, TTEC Holdings discloses that its EVP of TTEC Engage Martin Deghetto sold 20K shares of common stock on August 7th in a total transaction size of $1.15M.

17:21 EDT CoreCivic to replace Valaris in S&P 600 at open on 8/17

17:20 EDT G-III Apparel, Levi Strauss renew U.S. licensing agreements for outerwear - G-III Apparel (GIII) announced that it has renewed its license agreements with Levi Strauss (LEVI) for the Levi's and Dockers brands. These licenses have been renewed through November 30, 2024 and cover men's and women's outerwear under the Levi's brand and men's outerwear for the Dockers brand. Levi's men's and women's outerwear collections will continue to be sold in select department stores, specialty stores and premium outerwear retailers, as well as Levi's retail locations. Dockers men's outerwear will be available at select department stores nationwide.

17:17 EDT StoneCo enters combination agreement with Linx - StoneCo (STNE) announces that it has signed a definitive agreement for STNE Participacoes S.A., a controlled company of Stone that holds the software investments business of the Stone group in Brazil, to merge its business with Linx (LINX), a provider of retail management software in Brazil. Immediately after the Merger, each StoneCo Class A preferred share will be redeemed for a cash payment of R$ 30.39, and each STNE Class B preferred share will be redeemed for 0.0126774 Stone Class A share.

17:03 EDT Tesla up over 6% at $1,465 per share after announcing stock split

16:59 EDT Tesla announces 5-for-1 stock split

16:44 EDT SeaSpine announces limited commercial launch of Explorer TO System - SeaSpine announced the limited commercial launch of the Explorer TO System. Explorer TO represents SeaSpine's first new product offering since 2017 in the estimated $400M expandable interbody market. The system provides a posterior interbody solution that offers both parallel and lordotic expansion options to fit patient anatomy, as well as surgeon preference.

16:41 EDT Wolverine World Wide announces Brendan Hoffman as president, future CEO - Wolverine World Wide (WWW) announced the appointment of Brendan Hoffman as its next president and his appointment as a member of its board, both effective on his expected start date of September 8. Hoffman will report to Blake Krueger, Wolverine Worldwide's current chairman, CEO and president. He is expected to transition over a period of time to become the future CEO of the company. Hoffman brings 30 years of merchandising, digital marketing and omni-channel consumer direct experience from a variety of brands and retailers. Most recently, he was CEO of Vince Holding (VNCE). While at Vince, Hoffman increased the growth and penetration of the e-commerce and digital platforms, adapted Vince's vertical supply chain and extended the brand into new consumer categories.

16:36 EDT Facebook removes 8.7M pieces of terrorism content in Q2 - Facebook said that it removed about 8.7M pieces of content categorized as terrorism in Q2. "On Facebook, the amount of content we took action on increased from 6.3 million in Q1 to 8.7 million in Q2," the company said. "And thanks to both improvements in our technology and the return of some content reviewers, we saw increases in the amount of content we took action on connected to organized hate on Instagram and bullying and harassment on both Facebook and Instagram." "Despite the impact of COVID-19, improvements to our technology enabled us to take action on more content in some areas, and increase our proactive detection rate in others," Facebook added. "Our proactive detection rate for hate speech on Facebook increased 6 points from 89% to 95%. In turn, the amount of content we took action on increased from 9.6 million in Q1 to 22.5 million in Q2. This is because we expanded some of our automation technology in Spanish, Arabic and Indonesian and made improvements to our English detection technology in Q1. In Q2, improvements to our automation capabilities helped us take action on more content in English, Spanish and Burmese. On Instagram, our proactive detection rate for hate speech increased 39 points from 45% to 84% and the amount of content we took action on increased from 808,900 in Q1 2020 to 3.3 million in Q2. These increases were driven by expanding our proactive detection technologies in English and Spanish." Reference Link

16:24 EDT Health Catalyst to acquire Vitalware - Health Catalyst announced that it has entered into a definitive agreement to acquire Vitalware, a Yakima, Washington-based provider of revenue workflow optimization and analytics SaaS technology solutions to healthcare organizations. Health Catalyst expects to fund the transaction using a mix of stock and cash. The parties expect the transaction, which is subject to customary closing conditions, to close in Q3 or Q4 of 2020.

16:16 EDT Invesco reports preliminary AUM $1.195T as of July 31 - An increase of 4.4% versus previous month-end.

16:15 EDT Tenet says Conifer leadership change not expected to impact spin schedule - After Tenet Healthcare announced that Joseph Eazor has stepped down as CEO of Conifer Health Solutions, effective at the end of August, Executive Chairman and CEO Ron Rittenmeyer said, "We respect Joe's decision and are sorry to see him leave at this time. He had made solid contributions during his short tenure. In the past three months, Conifer has significantly strengthened its team with the additions of Arvind Ramakrishnan as Chief Operating Officer and Matt Bayley as Chief Commercial Operations Officer, which will help ensure continued exceptional performance. We do not expect this change will impact the spin schedule or any of our operations. And we have begun the process of evaluating candidates for CEO."

16:09 EDT Super Micro Computer authorizes stock repurchase of up to $30M - Super Micro Computer announced that, its Board of Directors has authorized a stock repurchase program pursuant to which the Company may repurchase up to $30 million of its common stock. The stock repurchase program is effective until December 31, 2020 or until the maximum amount of common stock is repurchased.

16:07 EDT AzurRx announces results from Phase 2 combination therapy MS1819 trial - AzurRx BioPharma announced positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency, EPI, n patients with cystic fibrosis, CF. In the primary efficacy analysis, patients receiving MS1819 in combination with PERT therapy achieved a clinically meaningful improvement in the coefficient of fat absorption, CFA, at each of the three dose levels, with no adverse safety events reported. Additionally, patients showed improvements in the key secondary endpoints, including body weight, stool consistency and reductions in the number of bowel movements and the incidence of steatorrhea. Results from the initial five patients in the trial show an improvement in CFA above 80% across all dose levels and on all visits. Mean CFA at the 700mg/day, 1200 mg/day and 2240 mg/day doses of MS1819 plus standard of care were 88.4%, 87.2% and 86.5% respectively, compared to baseline level (78.4%). This represents an average increase of 9 points in CFA during the trial. "We are thrilled to see such consistently positive responses from these initial patients in our ongoing Phase 2 combination therapy trial with MS1819. EPI is a very challenging disease with many CF patients unable to achieve healthy nutrition even when using the maximum number of allowed or tolerated PERT capsules, especially those in the moderate-severe categories," said James Sapirstein, Chief Executive Officer of AzurRx. "We look forward to completing treatment of all patients and announcing top line data in 2021."

16:02 EDT OneSpan not providing FY20 guidance - The company states: "Given the increased uncertainty about the impact of the pandemic on the global economy and our customers, the Company believes it prudent to withdraw its previously issued full-year guidance. Management will provide additional commentary during its second quarter earnings conference call. "

15:35 EDT Eastern Company announces acquisition of Hallink RSB Inc. - The Eastern Company announced that it has acquired specific assets of Hallink RSB Inc., a supplier of blow molds and change parts to the food, beverage, healthcare and chemical industry. The company did not disclose the terms of the transaction.

15:15 EDT Microsoft's LinkedIn says SlideShare acquired by Scribd - The Corporate Communications team at Microsoft's LinkedIn announced in a blog post that "digital library leader" Scribd has acquired LinkedIn's SlideShare. "On September 24, Scribd will begin operating the Slideshare business, its 100 million users, along with its presentation upload and hosting tools, and tremendous archive of presentations and documents. LinkedIn acquired SlideShare in May 2012 at a time when it was becoming clear that professionals were using LinkedIn for more than making professional connections. Over the last eight years, the SlideShare team, product, and community has helped shape the content experience on LinkedIn. We've incorporated the ability to upload, share, and discuss documents on LinkedIn... We are not disclosing the financial terms of the deal." Reference Link

15:05 EDT Big Ten Conference postpones 2020-2021 fall sports season - The Big Ten Conference announced the postponement of the 2020-21 fall sports season, including all regular-season contests and Big Ten Championships and Tournaments, due to ongoing health and safety concerns related to the COVID-19 pandemic. In making its decision, which was based on multiple factors, the Big Ten Conference relied on the medical advice and counsel of the Big Ten Task Force for Emerging Infectious Diseases and the Big Ten Sports Medicine Committee. The fall sports included in this announcement are men's and women's cross country, field hockey, football, men's and women's soccer, and women's volleyball. The Big Ten Conference will continue to evaluate a number of options regarding these sports, including the possibility of competition in the spring. Decisions regarding winter and spring sports will also continue to be evaluated. Publicly traded companies in the gambling space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

14:25 EDT Hermitage Offshore trading halted, news pending

13:51 EDT Vireo Health completes sale of PAMS stake to Jushi Holdings for $37M - Vireo Health (VREOF) announced that it completed the sale of its equity in Pennsylvania Medical Solutions, or "PAMS," to Jushi Inc, a subsidiary of Jushi Holdings (JUSHF), for a total consideration of $37M. Vireo management expects to utilize a portion of the transaction proceeds for capital expenditures that will increase scale in its core markets of New York, Minnesota, Maryland, Arizona, and New Mexico. "These development projects are expected to significantly improve the company's near-term revenue and profitability outlook, and management anticipates discussing these development projects and other impacts of this transaction in more detail during the company's upcoming second-quarter earnings conference call in late August," Vireo stated. Vireo Founder and CEO Kyle Kingsley added: "The successful sale of our equity in Pennsylvania Medical Solutions helps to secure Vireo's capital position for the foreseeable future and enables us to comfortably execute our fiscal year 2020 operating strategy. We expect to begin generating positive cash flow in the first half of 2021 without requiring any additional capital infusions."

13:15 EDT Linx SA (ADS) trading resumes

13:07 EDT Holland America extends pause of cruise operations to departures through Dec. 15 - Carnival's Holland America Line is extending its pause of cruise operations and cancelling departures on all ships through Dec. 15, 2020. The pause extension affects Caribbean, Mexico, Panama Canal, Pacific Coastal, South America, Antarctica, Hawaii, South Pacific, Australia and Asia itineraries. As previously announced, Holland America Line paused global cruise operations and cancelled all Alaska, Europe and Canada/New England cruises for 2020; additional departures from the port of Vancouver, British Columbia, Canada, in 2020; and select Hawaii itineraries for early 2021.

12:25 EDT Qualcomm jumps 4% after appeals court reported to vacate antitrust ruling

12:10 EDT Bristol-Myers says Health Canada approves Opdivo-Yervoy combo - Bristol Myers Squibb Canada announces Health Canada's approval of OPDIVO in combination with YERVOY with two cycles of platinum-double chemotherapy for the treatment of patients with metastatic non-small cell lung cancer, with no Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase tumour aberrations and no prior systemic therapy for metastatic NSCLC. Unlike traditional cancer therapies that target the tumour directly, immuno-oncology activates the body's own immune system to help recognize and attack cancer cells. This approval marks the availability of the first dual immuno-oncology plus limited course chemotherapy NSCLC treatment in Canada. "Despite NSCLC being the most common form of lung cancer, every patient's lung cancer and treatment journey is unique," says Dr. Rosalyn Juergens, Associate Professor at McMaster University in the Department of Oncology, Division of Medical Oncology. "This approval provides a novel dual immuno-oncology-based option that may provide longer survival for patients within the Canadian treatment landscape." The Health Canada approval was based on results from the randomised phase III clinical trial CheckMate -9LA. The study met both its primary and key secondary endpoints, demonstrating superior overall survival, progression-free survival and overall response rate for the dual immunotherapy plus limited chemotherapy combination versus chemotherapy alone.

12:07 EDT Linx SA (ADS) trading halted, news pending

12:01 EDT Northwest Biotherapeutics completes financing for $8M - Northwest Biotherapeutics announced that the company has completed a financing on favorable terms for approximately $8M. The company anticipates that this financing will help maintain the company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further broadens the lock-up of warrants that the company has been building.

12:00 EDT Large Cap Growth Index-Linked ETN rises 1225.3% - Large Cap Growth Index-Linked ETN is up 1225.3%, or $168.29 to $182.03.

11:59 EDT Moderna uncertain about COVID-19 vaccine patent exclusivity - In a regulatory filing, Moderna said last week said: "We may not hold proprietary rights to some patents required for us to develop, manufacture, and commercialize our proposed products. Because certain U.S. patent applications are confidential until the patents issue, such as applications filed prior to November 29, 2000, or applications filed after such date which will not be filed in foreign countries, third parties may have filed patent applications for technology covered by our pending patent applications without our being aware of those applications, and our patent applications may not have priority over those applications. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions, including mRNA-1273." It added that "For this and other reasons, we may be unable to secure desired patent rights, thereby losing exclusivity. Further, we may be required to obtain licenses under third-party patents to market our proposed products or conduct our research and development or other activities. If licenses are not available to us on favorable terms, we may not be able to market the affected products or conduct the desired activities."

11:38 EDT Exxon Mobil, Global Clean Energy sign renewable diesel agreement - ExxonMobil has signed an agreement with Global Clean Energy Holdings to purchase 2.5 million barrels of renewable diesel per year for five years from a converted California refinery starting in 2022. The renewable diesel will be sourced from a refinery acquired by Global Clean Energy in Bakersfield, California, which is being retooled to produce renewable diesel from Global Clean Energy's patented varieties of camelina, a fallow land crop that does not displace food crops, and other non-petroleum feedstocks. Following scheduled production startup in 2022, ExxonMobil plans to distribute the renewable diesel within California and potentially to other domestic and international markets. "Our agreement with Global Clean Energy builds on ExxonMobil's longstanding efforts to develop and offer products that help meet society's energy needs while reducing environmental impacts," said Bryan Milton, president of ExxonMobil Fuels and Lubricants Company. "Chemically similar to petroleum-based diesel, renewable diesel can be readily blended for use in engines on the market today."

11:17 EDT Hudson Technologies closing bid price back in compliance with Nasdaq minimum - Hudson Technologies announced that it received a letter from The Nasdaq Stock Market indicating that the closing bid price of the company's common stock has been at $1.00 per share or greater for ten consecutive business days. Accordingly, Hudson has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed, the company said.

11:03 EDT Standard Chartered, Microsoft announce three-year strategic partnership - Standard Chartered Bank (SCBFF) and Microsoft Corp. (MSFT) announced a three-year strategic partnership to accelerate the bank's digital transformation through a cloud-first strategy. This partnership marks a significant milestone for Standard Chartered in making its vision for virtual banking, next-generation payments, open banking and banking-as-a-service a reality. Leveraging Azure as a preferred cloud platform, the companies will also co-innovate in open banking and real-time payments to help the bank unlock new banking experiences for clients. As part of its digital transformation, Standard Chartered will adopt a multicloud approach, where significant applications, including its core banking and trading systems and new digital ventures such as virtual banking and banking-as-a-service, will be cloud-based by 2025, subject to regulatory approvals. The bank will also adopt a cloud-first principle for all new software developments and major enhancements.

10:36 EDT Google releases virtual visiting cards on Google Search in India - In a blog post, Lauren Clark, product manager for Google Search, said, " If you're a business professional, performer, or anyone looking to build up your own online presence, you might have a website, social profiles, and other information spread across many sites. If you're just getting started, you may not have a website or much of an online presence at all. Today, we are solving these challenges with a new feature called people cards. It's like a virtual visiting card, where you can highlight your existing website or social profiles you want people to visit, plus other information about yourself that you want others to know. Creating a people card is easy. First, sign into your Google Account, then simply search for your name or "add me to Search" and tap the prompt that appears. To start building your people card, you can choose to include the image from your Google account, add a description of yourself, links to your website or social profiles, and, if you want, a phone number or email address. The more information you provide, the easier it is for people to find you. Our goal with Search is to always make sure people can find helpful and reliable information, so we have a variety of protections and controls in place to maintain the quality of information on people cards. Only one people card is allowed per Google Account, and a phone number is required to authenticate the account." Reference Link

10:30 EDT Addus HomeCare sees Q3 revenue cut 2%-3% vs. Q1 run rate due to COVID-19 - Comments taken from Q2 earnings conference call.

10:18 EDT Sysco pursuing additional cost savings opportunities

10:06 EDT Sysco removed about $500M of operating expenses in Q4 - Comments taken from Q4 earnings conference call.

10:01 EDT ExlService renews contract with Centrica - EXL announced a five-year contract extension to continue providing a comprehensive suite of services and solutions to Centrica. EXL will leverage domain, digital and analytics capabilities to deliver better business insights and help Centrica increase efficiency and improve customer experience.

10:00 EDT Daily S&P Biotech Bear 3x Shares falls -93.4% - Daily S&P Biotech Bear 3x Shares is down -93.4%, or -$46.69 to $3.31.

10:00 EDT iShares Goldman Sachs Technology rises 2074.3% - iShares Goldman Sachs Technology is up 2074.3%, or $287.75 to $301.62.

09:56 EDT Sysco sees gross margin reflecting topline mix changes, otherwise stable in FY21

09:55 EDT Sysco: Exit rate of FY20 was profitable, better than expected - Comments taken from Q4 earnings conference call presentation slides.

09:32 EDT Perrigo to acquire three Eastern European OTC skincare brands from Sanofi - Perrigo (PRGO) announced that it will acquire three Eastern European OTC skincare and hair loss treatment brands from Sanofi (SNY). Trailing twelve months net sales ending June 30, 2020 for these products were approximately approximately $23M. Other terms of the transaction were not disclosed. The transaction is expected to close early in the fourth quarter, subject to customary closing conditions.

09:27 EDT Cornerstone Building Brands discloses ransomware attack - In a regulatory filing, Cornerstone Building Brands reported that on August 9 the company detected a ransomware attack impacting certain of its operational and information technology systems. "Promptly upon its detection of the attack, the company launched an investigation, notified law enforcement and engaged the services of specialized legal counsel and other incident response professionals. As of the date hereof, the company has recovered many of its critical operational data and business systems. Although the company is in the early stages of assessing the incident, based on the information currently known, the company does not expect the incident to have a material impact on its business, operations or financial condition. The company carries insurance, including cyber insurance, which it believes to be commensurate with its size and the nature of its operations," Cornerstone Building stated.

09:25 EDT ClearOne expands number of COLLABORATE Space meeting participants to 49 - ClearOne has expanded the number of participants visible during a COLLABORATE(R) Space meeting to 49. The 7x7 gallery view enables greater engagement between the host and participants in large meetings. Other new features have been added to enrich the experience.

09:23 EDT Kingstone Companies announces dismissal of complaint in putative class action - Kingstone said in a release, "Kingstone Companies announced that the United States District Court for the Southern District of New York has granted the defendants' motion to dismiss the amended complaint in the putative securities class action suit originally commenced in 2019 against the Company and certain current and former officers and directors, captioned Woolgar v. Kingstone Companies et al., 19 cv 05500 (S.D.N.Y.). Plaintiff sought to represent a class of persons or entities that purchased Kingstone securities between March 14, 2018 and April 29, 2019, and alleged violations of the federal securities law in connection with, among other things, the Company's loss reserves in light of the April 29, 2019 announcement regarding losses related to winter catastrophe events. The Court has permitted plaintiff to amend the complaint to attempt to cure the deficiencies identified by the Court in its opinion (to the extent plaintiff has a good faith basis to do so). The amended complaint, if any, would need to be filed by September 11."

09:21 EDT Sogou retains Duff & Phelps as independent financial advisor - Sogou announced that the special committee of the board of directors of the Company has retained Duff & Phelps as its independent financial advisor. The Special Committee was formed to review and evaluate the previously announced non-binding proposal included in a letter that the Board received on July 27 from Tencent Holdings. Under the Proposal, Tencent proposed to acquire all of the outstanding ordinary shares, including ordinary shares represented by American depositary shares, of Sogou that are not already owned by Tencent for $9.00 in cash per ordinary share or ADS. The Company cautions its shareholders and others considering trading the Company's securities that neither the Board nor the Special Committee has made any decision with respect to the Company's response to the Proposal.

09:19 EDT Summit Academy installs Vystar's RxAir 400 UV light air purification systems - Summit Academy, a private school that serves students with autism, has installed Vystar Corporation's RxAir 400 Ultraviolet light air purification systems into its classrooms, tapping RxAir's powerful Ultraviolet Germicidal Irradiation technology that inactivates or kills more than 99.99% of airborne viruses, bacteria and fungi, including multiple coronavirus strains, influenza, pneumonia, and strep.

09:17 EDT Medtronic to acquire Companion Medical, terms not disclosed - Medtronic announced the planned acquisition of privately-held Companion Medical, manufacturer of InPen - the only U.S. FDA-cleared smart insulin pen system paired with an integrated diabetes management app on the market. The addition of Companion Medical's InPen to the Medtronic portfolio expands the company's ability to serve people where they are in their diabetes journey and offer them a unique and expansive ecosystem of support - regardless of how insulin is delivered. The acquisition of Companion Medical builds upon prior Medtronic strategic acquisitions, including Nutrino and Klue, that form the building blocks to design powerful algorithms leveraging the company's deep data science and AI capabilities. With this latest acquisition, Medtronic will work to further advance the automation of insights and dosing capabilities to help alleviate burden regardless of the technology that's preferred for insulin delivery. In addition, Medtronic will look to expand the availability of InPen globally. The acquisition is expected to close within one to two months - subject to the satisfaction of certain customary closing conditions. The transaction is expected to be neutral to Medtronic's adjusted earnings per share in the current fiscal year, and accretive thereafter. In addition, it is expected to meet Medtronic's long-term financial metrics for acquisitions. Additional terms of the transaction were not disclosed.

09:15 EDT Philips launches Virtual Care Station - Royal Philips announced the launch of Virtual Care Station, a telehealth environment that delivers virtual care services in convenient neighborhood locations such as retail settings, libraries, town halls and universities. The pod-based solution connects provider and insurance networks, allowing health providers and patients to have a local, community-based choice for care. Whether in underserved rural or urban areas, Virtual Care Station helps deliver on the Quadruple Aim by giving patients access to virtual face-to-face care, and is designed to help improve clinical outcomes, lower costs and increase patient and staff satisfaction. Virtual Care Station is based on Philips technology developed for the ATLAS program, which was created to serve the healthcare needs of U.S. veterans.

09:13 EDT J Capital Research says STAAR Surgical 'overstated' sales in China by 33% - In a report published on Tuesday, J Capital Research claims that STAAR Surgical has "overstated sales in China by at least one-third," or $21.6M, which would mean that "all of the company's $14M in 2019 profit is fake." "After extensive research into STAAR's worldwide operations, with a focus on China, we have concluded that STAAR China sales are overstated by about 33%. Fake sales come at 100% margins and therefore translate directly into profit. That means that the roughly $21.6M in overstated Chinese sales in 2019 represent 152% of total company profit. In other words, without the fraud that we believe pervades the China business, STAAR is losing money," J Capital Research argues. Reference Link

09:08 EDT Envela subsidiary begins discussions to acquire Bluebonnet Sterling - Envela announced that its wholly owned subsidiary DGSE, has begun discussions to acquire the business assets of Bluebonnet Sterling. No definitive agreement has been reached and there can be no assurance that a definitive agreement will be reached. Headquartered in Dallas, Texas, Bluebonnet Sterling focuses on recommerce in vintage and estate sterling-silver jewelry and silverware. Envela's ongoing business strategy includes seeking acquisitions with synergies, creating value for its shareholders and enhancing its brand by expanding product offerings.

09:04 EDT Eton says partner has not yet received communication on EM-100 FDA review - Eton Pharmaceuticals reported that its partner has not yet received a communication from the U.S. Food and Drug Administration regarding its decision on the review of EM-100. EM-100's Generic Drug User Fee Act target action date was August 10th. The company is not aware of any information requests outstanding and expects the FDA to communicate a decision in the coming days.

09:02 EDT Calumet Specialty Products announces management changes - Calumet Specialty Products Partners announced that it has named L. Todd Borgmann as the Partnership's Senior Vice President & Interim CFO. Borgmann will assume the CFO duties on September 1 following an orderly transition with the current EVP & CFO, H. Keith Jennings, who has announced he will leave the organization effective August 31, 2020. As Interim CFO, Borgmann will help execute Calumet's ongoing transformation strategy to become a premier specialty products company. He will lead all treasury, tax, IT and capital market activities and be charged with managing the Partnership's balance sheet and improving its corporate finance capabilities. Calumet also named Vincent Donargo as the Partnership's Chief Accounting Officer effective August 10. Donargo has served as the Company's interim CAO since June of this year. He will lead Calumet's accounting function and will continue the work to improve the Company's internal controls. Borgmann has over twelve years of experience with Calumet, serving the Company across a diverse set of management roles. For the last five years, Borgmann served as Vice President of Supply & Trading, developing extensive knowledge of petroleum markets, refining operations and risk management. Borgmann has also served as Calumet's Vice President of Business Development and Director of the Partnership's White Oils and Petrolatums sales. Borgmann earned a Bachelor of Science in Industrial Engineering from Purdue University and a Masters of Business Administration from the University of Notre Dame.

09:01 EDT General Motors names John Stapleton as acting CFO, effective August 15 - General Motors announced John Stapleton, GM North America CFO, has been named acting global CFO, effective August 15. The appointment follows the resignation of Dhivya Suryadevara, executive vice president and CFO, who will leave the company for an external opportunity outside the automotive industry. GM will conduct an internal and external search for a successor.

08:57 EDT Predictive Oncology urges shareholders to approve compensation-related proposals - Predictive Oncology issued a letter to shareholders discussing the Company's recent accomplishments and voting recommendations from its Board of Directors for two proposals that are scheduled for shareholder vote on September 3, 2020. The company said, "Predictive Oncology is committed to executing our strategic vision to develop and commercialize an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value for our shareholders. Over the last six months we have been diligently assembling a portfolio of assets and aligning our capital and governance structures to help us achieve this vision. At our annual meeting on September 3, 2020, we are asking you to approve two important compensation-related proposals - repricing stock options for executives and key employees, and an increased share reserve for the stock incentive plan. Management and the Board considered these proposals carefully before recommending them for your approval, and we need your vote FOR these proposals. Approval is critical as we expand upon our considerable recent business accomplishments and enhance shareholder value by attracting and retaining talented management...At our Annual Meeting on September 3, 2020 you are being asked to approve a number of proposals that are described in our proxy statement that we filed with the Securities and Exchange Commission on July 29, 2020 and have mailed to our stockholders. Two of the proposals are vital to retaining and attracting top talent aligned with executing our corporate strategy such that we can scale and grow our business and achieve profitability...The Board has determined that adverse changes in the market price of the Company's common stock since the Eligible Options were granted could materially interfere with the Company's efforts to retain the service of its existing officers and employees. In Proposal No. 3, Predictive is seeking approval of a one-time repricing of all stock options outstanding under the Company's Amended and Restated 2012 Stock Incentive Plan held by current officers or employees of the Company which have an exercise price higher than $1.54 per share, but excluding stock options granted for service on the Board of Directors. More specifically, the proposal requests stockholder approval to change the exercise price of eligible options to $1.54 per share, equal to the closing sale price of the common stock on July 1, 2020, the day before the Board approved the repricing. The Board recommends the option repricing to encourage an increasing alignment of their interests with those of the Company's stockholders and their stake in the long-term performance and success of the Company. When the market price for the Company's common stock is significantly below the applicable exercise price of an option, for example, the Board believes that the option holder is not likely to exercise that option and will not have the desired incentive that the option was intended to provide....Proposal No. 4: Increase in Reserve in Stock Incentive Plan. The Company does not possess enough options in its stock incentive option plan to incentivize valued employees currently working hard to bring success to Predictive and align their incentives with our shareholders. It is also critical to have a large enough share reserve under the plan to attract prospective employees to our organization. In order to meet its business and growth objectives, the company will need to hire talented additional management and operating personnel. In Proposal No. 4, Predictive is requesting stockholder approval to increase the share reserve by 750,000 shares, to a total of 1,750,000 shares. Currently, options to purchase 830,488 shares of common stock are subject to outstanding stock options under the Restated Plan. In determining the amount of the increase in the Restated Plan, the Predictive Board carefully considered its intention to grant further equity awards to current and future executive officers and key employees and directors. The Restated Plan also eliminates certain limitations on individual awards that are no longer required under applicable tax laws. The Board believes that approval of Proposal No. 4 is in the best interests of Predictive and its stockholders because the availability of an adequate number of shares reserved for issuance is important in attracting, retaining and motivating employees, consultants and directors in order to achieve the company's long-term growth and profitability objectives."

08:53 EDT XpresSpa announces dismissal of lawsuit filed by Moreton Binn, Marisol Binn - XpresSpa Group announced that U.S. District Court Judge Gregory Woods dismissed the purported derivative lawsuit that was filed in Manhattan federal court in June 2019 by Moreton Binn and Marisol Binn against XpresSpa; certain of its current and former directors; Rockmore Investment Master Fund, L.P.; B3D, LLC; and Brian Daly. On October 23, 2019, XpresSpa and the other defendants filed a motion to dismiss the complaint in its entirety and with prejudice. On July 13, 2020, Magistrate Judge Sarah Cave issued a 76-page Report and Recommendation recommending that Judge Woods grant XpresSpa's motion to dismiss in its entirety for three independent reasons: the Binns had failed to make a pre-suit demand on XpresSpa's independent Board of Directors; the Binns were not fair and adequate representatives of XpresSpa's shareholders for the purposes of a derivative lawsuit, as there was "evidence of 'economic antagonisms' between Plaintiffs and Defendants" and "the Binns hav[ing] an outsized personal interest in this litigation," and that these facts "illustrate a potential vindictiveness by the Binns towards Defendants"; and the Binns failed to state any plausible claims for relief with respect to any of their claims. Magistrate Judge Cave also recommended to Judge Woods that the Binns' request to amend their complaint be denied because it "would be allowing them a 'third bite at the apple.'" The Binns did not object to the Report and Recommendation, and Judge Woods adopted the Report and Recommendation in its entirety on August 6, 2020, thereby dismissing all of the Binns' claims with prejudice, meaning that the Binns cannot re-litigate these claims again. This was the third lawsuit that the Binns or their longtime counsel have brought against XpresSpa and its former and current directors and certain other parties in the past two years. A different federal judge had previously dismissed the two earlier lawsuits.

08:51 EDT Sarepta, University of Florida collaborate for rare genetic disease therapies - Sarepta Therapeutics and the University of Florida announced a strategic collaboration to enable cutting-edge research for novel genetic medicines. Through the agreement, Sarepta will fund multiple research programs at the University, and will have an exclusive option to further develop any new therapeutic compounds that result from the funded research programs. Through the collaboration, currently unique to UF, funding has been allocated for four innovative projects. These projects include exploratory research in novel gene therapy vectors, next-generation capsids and gene editing technologies as well as work in new therapeutic areas in degenerative genetic diseases. The goal is to foster early relationships with experts and accelerate the scientific advancements that lead to the development of transformational precision genetic medicines for patients in need.

08:48 EDT Bellerophon appoints Wassim Fares as CMO - Bellerophon Therapeutics (BLPH) announced that it has appointed Wassim Fares, M.D., MSCR, as CMO. Most recently, Dr. Fares was Senior Medical Director at Janssen Pharmaceutical Company (JNJ) and a member of Janssen's Pulmonary Hypertension therapeutic area development leadership team.

08:46 EDT Sono-Tek submits application for uplisting to Nasdaq Capital Market - Sono-Tek Corporation announced that it has submitted an application to uplist its common stock to the NASDAQ Capital Market. Acceptance for listing the Company's shares is subject to approval and satisfaction of several factors, including minimum listing requirements for the Nasdaq Capital Market. The Company is optimistic that it can satisfy all of the applicable listing requirements, however, there is no assurance that its application will be approved.

08:44 EDT Westport publishes inaugural ESG report - Westport Fuel Systems released their inaugural Environmental, Social and Governance Report outlining the Company's progress and focus on strengthening ESG performance and enhanced disclosures. This ESG report follows our prior year Sustainability Report and will be a valuable tool for investors and stakeholders to review Westport Fuel Systems' key material ESG topics, opportunities and performance. The highlights of the Report include:Our first opportunity to provide a global year-over-year comparison on performance, Additional reporting on Global Reporting Initiative disclosures compared to our 2018 Report, Expanded sections of our Code of Conduct for a more user-friendly and engaging document, An enhanced metrics-based overview of ethics and compliance training for all employees, A 12% reduction in global recordable injury rate, Reductions in both energy and GHG emissions intensity, Installation of 650 solar panels on our facility in Eindhoven, Netherlands, New baseline data on total global training hours per employee to enable future year-over-year comparisons, and the achievement of a gender-balanced Board of Directors in April 2020

08:38 EDT American Resources acquires 2 additional continuous miners for PCR - American Resources Corporation said in a release, " the Company has signed a contract to acquire two additional continuous miners for their Perry County Resources, or PCR, mining complex in Hazard, Kentucky. The PCR complex was acquired in September 2019 and has undergone a major restructuring. In anticipation of restarting the PCR complex within the next thirty days, American Resources is expanding its fleet of continuous miners to fit its restructured and low-cost operating model. With the addition of the two continuous miners the Company will now have six continuous miners as it restarts and ramps production."

08:37 EDT Iteris awarded $5.4M contract extension from the MTC for traveler services - Iteris announced the Metropolitan Transportation Commission, or MTC, has awarded Iteris a $5.4M contract extension to continue its use of Iteris' next-generation traveler information services solution to power the San Francisco Bay Area's 511 traveler information system. the new contract extension will continue this partnership a further two years. Under the terms of the contract extension with the MTC, Iteris will continue to operate and maintain the 511 SF Bay interactive voice response system, and provide regional transit data integration, software support and technical services for the MTC's 511 Operations Center.

08:36 EDT Revance says SAKURA 3 safety and efficacy results consistent with SAKURA 1, 2 - Revance said in a release, "Revance Therapeutics announced the publication of two separate peer-reviewed articles in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery, or ASDS. The two peer-reviewed publications reported efficacy data as well as detailed safety results from the SAKURA 3 Phase 3 open-label, long-term safety study. The SAKURA 3 study is part of the largest Phase 3 clinical development program for a neuromodulator in the treatment of glabellar lines. The Phase 3, open-label, multicenter trial evaluated single and repeat treatments in subjects receiving DaxibotulinumtoxinA for Injection for the treatment of moderate or severe glabellar lines. The study was conducted at 65 centers and with a total of 2,691 enrolled subjects who received one to three doses of DaxibotulinumtoxinA for Injection for a total of 3,830 treatments. In the first paper, the efficacy of DaxibotulinumtoxinA for Injection was not only highly consistent across successive treatment cycles and multiple end points evaluating response rates and duration of effect, but also confirmed results seen in the pivotal Phase 3 trials. Results that were found to be complementary to SAKURA 1 and 2 included: Median duration for return to moderate or severe wrinkle severity was 24 weeks; and Median time to return to baseline severity was 28 weeks. Additional results include high response rates (based on the proportion of patients achieving none or mild severity) on the Investigator Global Assessment-Frown Wrinkle Severity (IGA-FWS) scale seen after each of the three treatments."

08:33 EDT Immutep granted patent for eftilagimod alpha in chemo-immunotherapy combination - Immutep announced the grant of a new patent entitled "Combined Preparations for the Treatment of Cancer" by the United States Patent Office. This United States patent follows the grant of the corresponding European, Australian and Japanese patents and protects Immutep's intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod alpha and a chemotherapy agent. The chemotherapy agent is either a platinum-based anti-neoplastic agent, such as oxaliplatin or carboplatin, or a topoisomerase I inhibitor, such as topotecan. This new patent highlights the ongoing and important steps being taken by the Company to protect its lead product candidate in a range of novel and highly relevant combination formats, in both chemo-immunotherapy and other immunotherapy settings.

08:32 EDT Super League Gaming, GreenlightGo partner for virtual studio situation - Super League Gaming and GreenlightGO have partnered to provide GreenlightGO's extensive marketplace of production companies, producers, directors, and network production executives with Super League's virtual production studio system, deployed through SuperLeagueTV. A fully-remote, cloud-based solution that solves the challenges of producing broadcast-quality content during COVID, SuperLeagueTV enables reliable creation and omni-channel distribution of live and live-to-tape programs across digital and linear platforms.

08:25 EDT ADT Inc. joins the Zigbee Alliance - ADT has joined the Zigbee Alliance and the Project Connected Home over IP working group. ADT will help to develop and promote the adoption of Project CHIP, a new royalty-free connectivity standard to increase interoperability among smart home products, with security as a fundamental design tenet.

08:24 EDT PPG raises Q3 sales volumes guidance to down 6%-11% from down 8%-15% - PPG said in a release, "PPG announced that aggregate company net sales for July exceeded the company's original estimate, reflecting a continuation of the solid demand recovery experienced in June. Due to the stronger sales performance in July, the company now expects third quarter 2020 sales volumes versus the third quarter 2019 to be down 6% to 11%, excluding foreign currency translation, compared to the previously expected year-over-year decrease of 8% to 15%. In addition, the company now expects third quarter operating margin decrements to be between 10% to 15%, which is better than the approximate 25% experienced in the second quarter of 2020. The better margin decrements are due to strong operating margin leverage from higher than anticipated sales volumes coupled with continued strong cost management."

08:21 EDT OncoCyte to hold KOL webinar on DetermaIO clinical data - Oncocyte Corporation announced that it will host a webinar showcasing data on DetermaIO. The webinar will be held on Wednesday, August 19th at 11:30 a.m. PDT and is open to both clinicians and investors. Results from studies in non-small cell lung cancer and triple negative breast cancer will be presented. There are close to 3,000 ongoing immune-therapy clinical trials in the US alone, and up to 750,000 patients who may be eligible for immunotherapy treatment each year. DetermaIO is a novel classifier that assesses the tumor microenvironment based on gene expression measurement of 27 genes, and in clinical studies which will be presented in this webinar, has shown the ability to identify responders as well as non-responders to immune checkpoint inhibitor therapies. In studies presented at SITC 2019 and ASCO 2020, the test was shown to outperform the current standard of care biomarkers PD L1 and Tumor Mutational Burden. DetermaIO is currently available to pharmaceutical companies for use in research and clinical trials only.

08:17 EDT SurveyMonkey launches tech partner program - SurveyMonkey announced the launch of the SurveyMonkey Technology Ecosystem Program, an expanded partner platform that addresses enterprises' growing and evolving needs to generate stakeholder feedback and channel it into direct action. Built on an already-robust partner ecosystem, STEP will help companies of all sizes build, launch, amplify, and scale their SurveyMonkey integrations with developer resources and go-to-market opportunities provided by SurveyMonkey. Existing STEP partners include Zendesk, HubSpot, MailChimp, Constant Contact, Gainsight, and Freshworks, all of whom are integrating with SurveyMonkey to enable joint users to leverage the power of feedback to drive growth and innovation.

08:14 EDT Gilead says China NMPA approves Truvada for PrEP - Gilead said in a release, "Gilead Sciences announced that the China National Medical Products Administration, or NMPA, has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF). In China, Truvada for PrEP is indicated in combination with safer sex practices for pre-exposure prophylaxis, or PrEP, to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg. Truvada for PrEP should be taken once daily and used together with safer sex practices. Individuals must have a negative HIV-1 test immediately prior to initiating Truvada for PrEP."

08:12 EDT Kitov to activate up to eight sites in NT219 trial over next few months - The company said, "The FDA accepted Kitov's IND to conduct a Phase 1/2 clinical trial of NT219. The primary objectives of the open-label Phase 1/2 trial are to evaluate safety, assess PK, identify the appropriate dose to be studied in the Phase 2 portion, and establish preliminary efficacy of NT219. We initiated the study in July and expect to activate up to eight sites in the U.S. and Canada over the next few months. "

08:10 EDT Kitov expects to begin Phase 1/2 trial of CM24 with nivolumab in 2H20

08:10 EDT Software Acquisition to acquire CuriosityStream through reverse merger

08:10 EDT TYME says HopES Sarcoma Phase II clinical trial will pass futility test - Tyme Technologies announced a positive outcome of an interim futility review for the HopES Sarcoma Phase II clinical trial that is evaluating TYME's lead cancer metabolism-based candidate, SM-88, as a potential oral treatment for patients with Ewing's Sarcoma and other high-risk sarcomas. "It is evident that the salvage cohort will pass the futility test and meet the criteria for expansion," said Sant Chawla, M.D., founder of the Sarcoma Oncology Center, Santa Monica, CA and principal investigator for the HopES Sarcoma trial. The interim futility review was completed in late July and, based on the analysis of the data and recommendations of Dr. Sant Chawla, the study will proceed with the current trial design as planned. The next major milestone in the HopES Sarcoma trial is expected in calendar year 2021. Sarcomas represents a great unmet medical need and significant opportunity for all stakeholders. There are more than 12,000 patients diagnosed each year without meaningful treatment options. "We are pleased to have reached this important point in the HopES Sarcoma trial and now await the final results of the trial to determine the potential of oral SM-88 in high-risk sarcomas in an effort to improve the lives of these patients with, what we believe could be, a better safer approach," said Giuseppe Del Priore, M.D., M.P.H., Chief Medical Officer at TYME. "To date, SM-88 has demonstrated encouraging tumor responses in 15 different cancers across four separate studies with minimal serious grade 3 or higher adverse events."

08:09 EDT Delta Apparel reports July sales up 10% year-over-year - Delta Apparel announced sales results for the month of July. Delta Apparel's net sales in July grew over 10% compared to the prior year period, with growth in each of its business units. The Delta Group and Salt Life segments reported year-over-year growth of 9% and 23%, respectively, in July. Robert Humphreys, the company's chairman and CEO, commented, "The start to our fourth quarter has exceeded our expectations with July double-digit net sales growth. This marked our fourth consecutive month of sequential sales improvement for both the Delta Group and Salt Life Group segments. We are particularly pleased to see a return to growth across all business units, with notable strength in our DTG2Go digital print business achieving an over 50% sales increase year over year. Sales of Delta Catalog products grew double digits, propelled by strength in the retail licensing channel and improving dynamics in other sales channels. The Soffe business delivered solid growth during July. Consumers continued to seek Soffe products across multiple distribution channels, including the Soffe consumer website which enjoyed 115% growth over the prior year. The momentum in our Salt Life business continued in July with approximately 60% growth in our key direct-to-consumer e-commerce and retail channels, in addition to double-digit growth in the wholesale channel." The company serviced customer demand during the June quarter and through July primarily with its on-hand inventory position in the United States. By the end of June, all manufacturing facilities were operating and producing inventory to meet current market demand. While the ramp-up of production has exceeded the company's expectations, the near term growth momentum, particularly for Delta Catalog products, may be somewhat hampered until inventory can be fully replenished.

08:05 EDT Sypris awarded contract from Leonardo DRS Naval Electronics, terms not disclosed - Sypris Solutions said in a release, "Sypris Electronics announced that it has received an initial contract award from the Leonardo DRS Naval Electronics business unit to manufacture and test electronic assemblies for a shipboard system. Production will begin in 2020. Terms of the agreement were not disclosed."

08:05 EDT Inspired Entertainment announces first VLT in WCLC - Inspired Entertainment announced its first Valor video lottery terminal, VLT, placement into Canada. Western Canada Lottery Corporation, or WCLC, acting on behalf of the Saskatchewan Liquor and Gaming Authority, or SLGA, selected Inspired to provide 100 premium Valor cabinets to be delivered in early 2021, following a formal Request for Quotation, or RFQ, process. Inspired will provide a suite of unique game themes specifically tailored for the Saskatchewan VLT market including integration with its wide area progressive jackpot. Inspired's Valor VLT is an open-standard G2S protocol cabinet that features dual 27" high definition floating screens and a superior sound system that delivers a unique and immersive experience.

08:03 EDT Clayton, Dubilier & Rice to acquire HD Supply's White Cap business in $4B deal

08:02 EDT HD Supply to sell White Cap business to Clayton, Dubilier & Rice for $2.9B - HD Supply Holdings announced that it has entered into a definitive agreement to sell its Construction & Industrial--White Cap business to an affiliate of Clayton, Dubilier & Rice for a purchase price of $2.9B in cash. Net proceeds from the sale are expected to be approximately $2.5B after taxes and transaction costs. The transaction is expected to close in October 2020, subject to customary regulatory approvals. HD Supply expects to use the net proceeds from this transaction to return capital to HD Supply shareholders, fund M&A activity and repay debt. A more detailed discussion around the use of proceeds will take place on our second-quarter earnings call in early September. Once the transaction is complete, John Stegeman, White Cap's current CEO, and Alan Sollenberger, White Cap's current President, are expected to continue to lead the Construction and Industrial business, which will include the White Cap, Home Improvement Solutions and Brafasco businesses.

07:56 EDT Larimar Therapeutics expects topline results from Phase 1 CTI-1601 trial in 1H21 - In July 2020, Larimar resumed dosing of patients in its Phase 1 clinical trial to evaluate the safety and tolerability of single ascending doses of CTI-1601 for the treatment of FA, allowing the program to continue moving forward. The trial was previously delayed due to the impact of the COVID-19 pandemic. Topline results are expected in the first half of 2021.

07:49 EDT Black Diamond expects to complete Phase 1 portion of BTDX-189 trial in 1H21 - Black Diamond continued to enroll and dose patients in the MasterKey-01 study, a Phase 1/2 clinical trial of BTDX-189, in line with projections at initiation of the study. The Company remains on track to complete the Phase 1 portion of the trial in the first half of 2021.

07:47 EDT GTT Communications notifies SEC of delayed 10-Q filing - In a regulatory filing on Monday, GTT said the filing of the company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2020 has been delayed. "In the course of closing the Company's books for the quarter ended June 30, 2020, the Company identified certain issues related to the recording and reporting of Cost of Telecommunications Services and related internal controls. Upon identifying these issues, the Company informed the Audit Committee of the Board of Directors and CohnReznick LLP, the Company's independent registered public accounting firm. The Company's management and the Audit Committee, with assistance from outside counsel and consultants, are reviewing these issues and assessing the effect, if any, on the Company's financial statements for the quarter ended June 30, 2020 and previously issued financial statements, as well as whether there are any material weaknesses in the Company's internal controls. At this time, the Company does not know whether the Review will identify any issues other than those described above. Although the Company plans to file the Form 10-Q as soon as possible after the completion of the Review, the Company does not anticipate filing the Form 10-Q on or before August 17, 2020."

07:45 EDT BridgeBio says 'adequately financed' through key readouts of core programs - The company said, "BridgeBio remains on track with each of its four core value drivers - acoramidis for ATTR cardiomyopathy, low-dose infigratinib for achondroplasia, AAV5 gene therapy for congenital adrenal hyperplasia, and encaleret for autosomal dominant hypocalcemia type 1- and the company believes it is adequately financed through key readouts for each of these programs. Notably, BridgeBio dosed the first child in its Phase 2 clinical trial of infigratinib in achondroplasia in July."

07:41 EDT Auxly's Kolab project partners with Greentec on vape recycling program - Auxly Cannabis Group announced that it is partnering with the electronic waste recycling leaders at Greentec to provide cannabis retailers with a free-of-charge solution for the recycling of vape pens, cartridges and batteries. This industry-wide sustainability effort is led by Kolab Project. Kolab Project-branded E-waste recycling bins will initially be available in participating Spiritleaf and Superette stores later this summer, with more retailers joining the program in coming months. Bins will accept vapes, cartridges and batteries from all licensed producers.

07:37 EDT Prudential to sell Prudential of Taiwan to Taishin Financial - Prudential Financial announced that it has entered into a definitive agreement with Taishin Financial Holding, a Taiwan-based financial institution, to sell Prudential Life Insurance Company of Taiwan Inc. Prudential Financial said in a release, "Under the terms of the agreement, Prudential Financial will sell 100% of its life insurance business in Taiwan. This transaction is consistent with Prudential Financial's strategic focus internationally on Japan and higher-growth emerging markets around the world. Completion of the transaction is subject to customary closing conditions, including regulatory approvals."

07:35 EDT Ares Genetics announces publication on next generation sequencing workflow - Ares Genetics announced the publication of a peer-reviewed study that demonstrates the feasibility of a highly accurate and reproducible sample-to-insight workflow for various clinical microbiology assays including the molecular identification of bacterial pathogens and their genetic markers of antibiotic resistance. The combined laboratory and bioinformatics workflow was developed following requirements of the U.S. Clinical Laboratory Improvement Act for laboratory-developed tests. The bioinformatics analysis workflow leverages the QIAGEN CLC Microbial Genomics ARESdb Module for detection of antibiotic resistance markers. Powered by artificial intelligence, Ares Genetics' ARESdb is a comprehensive, global and continuously updated proprietary knowledgebase on AMR markers and their diagnostic relevance. Under a license from Ares Genetics, the QIAGEN CLC Microbial Genomics ARESdb Module provides users information about diagnostic performance parameters for individual AMR markers at antibiotic compound resolution and thereby addresses a key limitation of public AMR databases. The workflow was validated in a study focused on particularly challenging and clinically prevalent multi-drug resistant ESKAPE pathogens including the WHO priority 1 pathogens. In this study, the workflow demonstrated greater than99% repeatability, reproducibility, and accuracy. Pathogens were correctly identified with 100% sensitivity and specificity, AMR markers with greater than95% sensitivity and greater than99% specificity, respectively. Ares Genetics currently offers NGS-based clinical microbiology assays for epidemiology, infection control and research via its AI-powered bioinformatics platform ares-genetics.cloud under the brand name ARESupa - Universal Pathogenome Assay. In a recently published multi-center study, Ares Genetics demonstrated that ares-genetics.cloud can also accurately predict antibiotic susceptibility based on complex DNA signatures that are interpreted by combining ARESdb with artificial intelligence. The combination of high-resolution NGS and AI-powered data interpretation can enable accurate as well as comprehensive molecular antibiotic susceptibility testing and has the potential to provide information on antibiotic therapy response much faster than current culture-based approaches. Microbial infections and antibiotic resistance have become major healthcare challenges with rapidly spreading antimicrobial resistance estimated to have caused 700,000 deaths globally in 2016, a number that is projected to dramatically increase to 10 million deaths annually by 2050 if no countermeasures are taken. While on July 9th 2020, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund aiming to bring two to four new antibiotics to patients by 2030, a recent white paper by Ares Genetics highlights the urgent need for novel diagnostic approaches to allow for rapid identification of causative pathogens and their susceptibility to available antibiotic options, in order to guide appropriate treatment of patients while enabling prudent and informed use of existing or future new antibiotics. The studies by Ares Genetics were supported through funding provided by the Vienna Business Agency and the Austrian Research Promotion Agency.

07:32 EDT AnPac Bio opens Philadelphia lab operations - AnPac Bio-Medical Science announced that the Company has commenced operations of its new Philadelphia lab, with the completion of its facility renovation and first phase equipment installation in July 2020. A Roche Cobas e411 machine, a diagnostic analyzer, which has received the FDA's Emergency Use Authorization for performing COVID-19 anti-body tests, is among the Laboratory's first phase equipment.

07:29 EDT DSS receives shareholder approval for Impact Biomedical acquisition - Document Security Systems announced its shareholders voted to approve the Company's acquisition of Impact BioMedical as outlined in the share exchange agreement announced on April 27, 2020, signed by DSS, DSS BioHealth Security, Impact BioMedical and Global BioMedical. Global BioMedical, which owns all of the stock of Impact BioMedical, is a 100% owned subsidiary of Singapore eDevelopment Limited. The DSS long-term plans include seeking to take Impact BioMedical public after the share exchange in an initial public offering. Prior to doing so, and in concert with this public offering, DSS anticipates a proposed dividend of Impact BioMedical shares to its shareholders, whereby for every one DSS share of common stock held, the shareholder would be entitled to a bonus of four Impact Shares, the Bonus shares. The planned Bonus share dividend would be divided into two tranches; the shareholders of record of a date to be determined but prior to initial public offering would be eligible for two shares for every share of DSS which they hold, and a second dividend of an additional two shares of Impact BioMedical if they were the shareholders of record on the date of the proposed IPO of Impact BioMedical. The issuance of the Bonus shares would occur after the registration and the IPO of Impact BioMedical's shares. While this statement represents the current intentions of DSS management and of its Board, there can be no assurance, however, that Impact BioMedical will be taken public and/or that any such Bonus Share distribution will occur. The Company's plans are in line with its mission of sharing its economic benefits by giving DSS shareholders bonus shares of its subsidiaries as they are spun out into IPO's. DSS announced its acquisition of Impact Biomedical in March 2020. Impact Biomedical's ownership of a suite of antiviral and medical technologies has been valued at $382M by Destum Partners, known globally for its high level of expertise and capability in independently valuing and advising on pharmaceutical technology. On May 26, 2020, Impact Biomedical disclosed that it received a valuation of $933M for this suite of technology from a different independent valuation firm. Unlike the previous valuation, the new valuation takes into consideration numerous additional disease applications of the suite of antiviral and medical technologies.

07:26 EDT Fulcrum Therapeutics on track to initiate Phase 1 trial of FTX-6058 in Q4 - On track to initiate Phase 1 trial of FTX-6058 in the fourth quarter of 2020. FTX-6058 is an oral small molecule therapeutic discovered by Fulcrum and designed to induce expression of fetal hemoglobin in red blood cells to compensate for the mutated adult hemoglobin in sickle cell disease. Preclinical data with FTX-6058 showed an increase in HbF levels up to approximately 30% of total hemoglobin. On-track to submit investigational new drug application in Q3 2020.

07:25 EDT Fulcrum Therapeutics expects to share topline data from ReDUX4 trial in 1Q21 - Announced interim data for ReDUX4, a Phase 2b trial of losmapimod, a selective p38alpha/beta mitogen activated protein kinase inhibitor, in facioscapulohumeral muscular dystrophy: Results from the interim analysis in the first 29 randomized subjects indicated that DUX4-driven gene expression did not separate from placebo at 16 weeks. In a pre-specified sensitivity analysis assessing biopsies with the highest pre-treatment level of DUX4-driven gene expression, treatment with losmapimod resulted in a 38-fold reduction in DUX4-driven gene expression as compared to the 5.4-fold reduction seen in the placebo arm. Results indicate that muscle biopsies within the higher range of DUX4-driven gene expression may be needed to observe a reduction from baseline. Secondary and exploratory endpoints were not assessed as part of this analysis. Remain on track to share topline results on the primary endpoint in the first quarter of 2021 and full data, including all secondary and exploratory endpoints, in the second quarter of 2021.

07:17 EDT Aemetis launches subsidiary Aemetis Health Products - Aemetis announced the launch of its new Aemetis Health Products subsidiary which is focused on the production and marketing of blended liquid and gel sanitizers as bulk and packaged products. As a result of the global COVID-19 pandemic, demand for high grade alcohol for sanitizer production increased significantly in early 2020. Aemetis Health Products will blend gel and liquid sanitizer for delivery in bulk as well as packaged form to customers. Aemetis is currently constructing plant upgrades of control systems and processing equipment that will enable the production of US Pharmacopeia medical grade alcohol at the Aemetis plant near Modesto, California.

07:12 EDT FibroGen enrolls first patient in Phase 3 pamrevlumab clinical trial - FibroGen announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with non-ambulatory Duchenne muscular dystrophy. The primary objective of this global study is to evaluate the effect of pamrevlumab on muscle function in patients with DMD. Approximately 90 patients will be randomized 1:1 to receive pamrevlumab plus systemic corticosteroids, or placebo plus systemic corticosteroids, for up to 52 weeks. The primary efficacy endpoint is the change in the total score of performance of upper limb assessment, from baseline to Week 52, and additional endpoints include pulmonary and cardiac function tests. Subjects who complete the 52-week study will be eligible for rollover into an open-label extension study with pamrevlumab and systemic corticosteroids.

07:11 EDT LabCorp to perform no-charge COVID-19 antibody test to increase plasma donations - LabCorp (LH) announced details of a no-charge antibody testing program in response to federal health authorities' request to increase donations of COVID-19 blood plasma. Plasma with COVID-19 antibodies may be helpful when treating patients with an active COVID-19 infection and is being evaluated as a possible treatment. For the next three months, LabCorp will perform the high-affinity antibody test at no charge to patients, insurance companies, or the government. When patients are receiving other medically necessary blood tests as part of a medically necessary exam or treatment, this program allows providers to add the SARS-CoV-2 Antibodies Test to the same order at no charge. The no-charge high-affinity antibody testing program will use only the Roche (RHHBY) Elecsys Anti-SARS-CoV-2 and does not apply to other COVID-19 antibody tests, such as the IgG test. Patients will be able to access their results through the LabCorp Patient portal and through their doctor. Result data from the antibody testing program will also be reported to the CDC and state public health agencies to further support COVID-19 surveillance and response efforts.

07:11 EDT Visa appoints Douglas Sabo as first chief sustainability officer - Visa said in a release, "Visa announced that yesterday it successfully priced its inaugural green bond offering, totaling $500M, paying a semi-annual coupon of 0.75% and maturing August 15, 2027. The green bond, believed to be the first issued by a digital payments network, will be used to help advance the company's commitment to environmental sustainability and a sustainable payments ecosystem. In support of that commitment and in addition to its inaugural green bond, Visa is also announcing the appointment of its first chief sustainability officer, Douglas Sabo." Visa CEO Al Kelly said, "At Visa, we see a responsibility and an opportunity to use the power of our network to drive broad shifts toward a sustainable future," said Al Kelly, chairman and chief executive officer of Visa Inc. "Our green bond offering will help us accelerate the transformation of our infrastructure and operations to reach our environmental goals. This commitment extends to appointing Visa's first chief sustainability officer, tasked with ensuring we continue to take bold and industry-leading actions on the environment."

07:08 EDT Bio-Techne announces release of new SARS-CoV-1/2 Recombinant Antibody - Bio-Techne announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain and blocks the virus from binding to its host receptor, ACE-2, inhibiting viral infection . The SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody is the first camelid antibody offering in our new LlaMABody product line. Additionally, it is the first commercially available antibody that is produced using the VHH72 CoV-2 RBD Blocking/Neutralization clone published in Cell by Wrapp, D. et al. This antibody reflects Bio-Techne's well-established expertise in recombinant antibody engineering as a growing segment in our business, especially in biopharma.

07:05 EDT Broadridge sees FY21 adjusted operating income margin increase of ~100 bps

07:04 EDT Broadridge raises annual dividend 6% to $2.30 from $2.16 per share - On August 10, Broadridge's Board of Directors declared a quarterly dividend of 57.5c per share payable on October 5 to stockholders of record on September 15. This declaration reflects the Board's approval of an increase in the annual dividend amount by 6% from $2.16 to $2.30 per share, subject to the discretion of the Board to declare quarterly dividends. With this increase, the company's annual dividend has increased for the 14th consecutive year since becoming a public company in 2007.

07:02 EDT Bicycle Therapeutics appoints Dominc Smethurst as Chief Medical Officer - Bicycle Therapeutics (BCYC) announced the appointment of Dominic Smethurst, as Chief Medical Officer. Smethurst brings to Bicycle extensive expertise in developing bispecific immuno-oncology agents, as well as toxin conjugate therapeutics for cancer and other serious diseases. Dominic Smethurst has over twenty years of experience working with leading pharmaceutical and biotechnology companies, clinical research institutions, and the UK's National Health Service. He was most recently a medical consultant, advising biopharma companies on clinical development strategies and licensing projects. Prior to that, he served as Chief Medical Officer of Tusk Therapeutics, an immuno-oncology company acquired by Roche (RHHBY), where he oversaw development of antibodies targeting CD25 and CD137, among others. Previously, as Vice President Oncology and Global Therapeutic Area Lead at Icon, a global contract research organization, he executed clinical trials involving numerous novel cancer treatments, including CAR-T therapies. Prior to that, Smethurst held physician leadership roles at AstraZeneca (AZN), Amgen (AMGN) and Adaptimmune (ADAP).

07:01 EDT Bristol-Myers reports CheckMate-577 trial meets primary DFS endpoint - Bristol Myers Squibb announced the Phase 3 CheckMate -577 trial evaluating Opdivo as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction cancer met its primary endpoint of disease-free survival, or DFS, at a pre-specified interim analysis. In the trial, treatment with Opdivo following neoadjuvant chemoradiation therapy and complete surgical resection demonstrated a statistically significant improvement in the primary endpoint of DFS compared to placebo in the all-randomized population. The safety profile of Opdivo was consistent with previously reported studies. This is the second tumor, in addition to melanoma, where Opdivo has demonstrated a benefit in the adjuvant setting, the company stated. The company will complete a full evaluation of the available CheckMate -577 data and work with investigators to share the results at an upcoming medical conference, as well as discuss them with health authorities. The CheckMate -577 trial will continue as planned to allow for future analysis of the secondary endpoint of overall survival, or OS, the company noted.

07:00 EDT Bristol-Myers: CheckMate-649 trial meets both primary endpoints - Bristol Myers Squibb announced that CheckMate -649, a pivotal Phase 3 trial evaluating Opdivo plus chemotherapy compared to chemotherapy alone as a first-line treatment for metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, met both primary endpoints of overall survival at a pre-specified interim analysis and progression-free survival at final analysis in patients whose tumors express PD-L1 with a combined positive score greater than or equal to 5. The OS benefit was also observed in the all-randomized population. Opdivo is the first and only PD-1 inhibitor to demonstrate superior OS and PFS in combination with chemotherapy when compared to chemotherapy alone in patients with gastric cancer, GEJ cancer or esophageal adenocarcinoma, the company said in a statement. The safety profiles of Opdivo and chemotherapy in this trial are reflective of the known safety profiles of Opdivo and chemotherapy in first-line gastric and esophageal cancers. The company will complete a full evaluation of the available CheckMate -649 data and work with investigators to share the results at an upcoming medical conference, as well as discuss them with health authorities. CheckMate -649 is also evaluating the Opdivo plus Yervoy combination compared to chemotherapy in patients with gastric cancer, GEJ cancer or esophageal adenocarcinoma. The company remains blinded to data from this arm and the trial continues in follow-up to allow the data to mature.

06:57 EDT Aecom says appointment of CEO W. Troy Rudd to take effect on August 15 - AECOM announced that the previously announced appointments of W. Troy Rudd as CEO and Lara Poloni as President will now take effect on August 15. In tandem with Rudd's appointment, the company has named Gaurav Kapoor, currently AECOM's Chief Accounting Officer, Global Controller and Treasurer, as CFO, effective August 15th. AECOM also announced that Douglas Stotlar has been appointed as independent Chairman of AECOM's Board of Directors and Mr. Rudd has been appointed as Director to the Board, effective August 15th. The appointments follow the previously announced departure of Michael Burke as Chairman and CEO. Stotlar has served on AECOM's Board since 2014, having previously served as a Director of URS Corporation since 2007 until its acquisition by AECOM in 2014. In addition, Bradley Buss has been appointed to the AECOM Board of Directors, effective August 10th.

06:53 EDT Protalix, Chiesi unit announce FDA acceptance of pegunigalsidase alfa BLA - Protalix, together with its development and commercialization partner Chiesi Global Rare Diseases, a unit of Chiesi, announced that the FDA has accepted the biologics license application, or BLA, and granted priority review designation for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease. The BLA was submitted via the FDA's Accelerated Approval pathway. Pegunigalsidase alfa is the company's long-acting recombinant, PEGylated, cross-linked alpha-galactosidase-A investigational product candidate. The FDA set an action date of January 27, 2021, under the Prescription Drug User Fee Act. The FDA also indicated in the BLA filing communication letter that it is not currently planning to hold an advisory committee meeting to discuss the application.

06:42 EDT Casper Sleep says 57 stores reopened as of June 30 - The company stated, "Casper is closely monitoring how the spread of the COVID-19 pandemic caused by the novel coronavirus is affecting its employees, customers and business operations. We have developed and implemented preparedness plans to help protect the safety of our employees and customers, while safely continuing business operations. In order to protect the health and safety of our employees, particularly given the severity of the pandemic in New York and California, we have continued to limit access to our corporate offices, and our corporate workforce has spent and continues to spend a significant amount of time working from home during this period. Access to our offices will remain limited until we are able to safely and responsibly re-open them on a broader basis in accordance with governmental and public health guidance, as well as health and safety policies tailored to our operations. In the second quarter, as regulatory restrictions on retail businesses have lifted or been modified, beginning in mid-May 2020, we have been reopening our retail store operations in North America in accordance with government and public health guidance. As of June 30, 2020, 57 of our stores have reopened. In each instance, available services vary based on the regulatory requirements and public health guidance applicable to that location, including walk-in shopping, private in-store appointments, curbside pick-up services, and virtual appointments. The health and safety of our customers and employees remain our top priority. We continuously monitor developments related to COVID-19 in locations where we have retail operations, and have developed procedures to enable us to responsibly and efficiently open or close our stores, and adjust our service offerings as needed in response to changing COVID-19 conditions and applicable guidance from government and public health officials. We are also working closely with our manufacturing, logistics and other supply chain partners to monitor key aspects of our product and delivery supply chain. To date, certain of our suppliers and logistics providers have temporarily experienced supply constraints or labor shortages due to the COVID-19 outbreak. As a result, we have been impacted by industry-wide capacity constraints which have led to increased delivery times for certain of our products through our e-commerce platform and impacted order fulfillment capabilities for certain of our retail partners. We are actively qualifying and on-boarding new suppliers and expect these additional capabilities to mitigate any inventory constraints within the upcoming quarter."

06:40 EDT ViacomCBS Networks International selects Intelsat for video distribution - Intelsat announced it has been selected to continue distributing content for ViacomCBS Networks International in Central Europe, Eastern Europe and across the Asia Pacific region. Intelsat was chosen for its unique ability to deliver managed media services, global coverage and integrated satellite distribution and terrestrial network. VCNI delivers premium content through notable brands such as BET, MTV and Nickelodeon to a worldwide audience of billions across both traditional and emerging platforms.

06:21 EDT Fennec sinks 34% after receiving FDA Complete Response Letter on NDA for PEDMARK - In pre-market trading, shares dropped 34% to $6.74.

06:14 EDT Catalyst receives Notic of Allowance for Diaminopyridine from USPTO - Catalyst Pharmaceuticals announced that the United States Patent and Trademark Office, or USPTO, has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/128,672. The allowed application, "Methods of Administering 3,4-Diaminopyridine", claims a method of treating a human patient diagnosed with a 3,4-DAP sensitive disease by administering 3,4-DAP to slow acetylating patients having certain mutations in each allele of the NAT2 gene.

06:09 EDT Check Point partners with Claroty to secure industrial control networks - Claroty announced its partnership with Check Point. The technical alliance between the two companies gives enterprises and infrastructure operators the real-time cybersecurity and visibility they need to protect OT and industrial control system networks from cyber attacks. This announcement follows the release of Check Point's Internet of Things, or IoT, Protect solution, which prevents IoT cyber attacks by adapting protections to any IoT or OT device across smart-office, smart-building, medical, and industrial environments. As one of Check Point's technology partners, Claroty supports the discovery and classification of OT devices in a variety of verticals, giving Check Point customers an integrated end-to-end security solution.

06:05 EDT Fennec receives FDA Complete Response Letter on NDA for PEDMARK - Fennec Pharmaceuticals announced that it received a Complete Response Letter on August 10 from the U.S. FDA regarding its New Drug Application for PEDMARK for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients greater than or equal to1 month to 18 years of age with localized, non-metastatic, solid tumors. According to the CRL, after recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK. The company plans to request a Type A meeting to discuss the issues and other matters that were described in the CRL pertaining to the steps required for the resubmission of the NDA for PEDMARK. Importantly, no clinical safety or efficacy issues were identified during the review and there is no requirement for further clinical data. "We are steadfast in our commitment to reducing the risk of life-long hearing loss for children receiving cisplatin chemotherapy who currently have no approved therapies for this devastating condition," said Rosty Raykov, CEO of Fennec. "We will work closely with our manufacturer and the FDA to fully address the issues raised in the letter as expeditiously as possible."

06:03 EDT MicroStrategy to purchase up to $250M of Class A common stock - MicroStrategy announced that it commenced a "modified Dutch Auction" tender offer to purchase up to $250M in value of shares of its issued and outstanding class A common stock, par value $0.001 per share, or such lesser number of Shares as are properly tendered and not properly withdrawn, at a price not greater than $140.00 nor less than $122.00 per Share, to the seller in cash, less any applicable withholding taxes and without interest. The closing price of the Shares on The Nasdaq Global Select Market on August 10, the last full trading day before the commencement of the tender offer, was $123.62 per Share. The tender offer is scheduled to expire at 5:00 P.M., New York City time, on September 10, unless the offer is extended or terminated.

05:51 EDT National Energy Services announces contract awards in UAE valued up to $100M - National Energy Services reported multiple contract awards in the United Arab Emirates valued at up to $100 million for Coiled Tubing, Nitrogen and Stimulation Services for a period of three years with two optional one-year extensions.

05:40 EDT Dr. Reddy's announces first-to-market launch of generic Ciprodex Otic Suspension - Dr. Reddy's Laboratories said in a release, "Dr. Reddy's Laboratories announced the launch of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the FDA. Dr. Reddy's Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle."

05:29 EDT Amazon launches Project Zero in seven new countries - Amazon said in a release, "Amazon announced the expansion of Project Zero to seven new countries - Australia, Brazil, Netherlands, Saudi Arabia, Singapore, Turkey, and the UAE - making it available in 17 countries where Amazon has a store. Project Zero combines Amazon's advanced technology, machine learning, and innovation with the sophisticated knowledge that brands have of their own intellectual property so we can together drive counterfeits to zero. Launched in 2019, Project Zero builds on Amazon's long-standing work and investments to ensure that customers always receive authentic goods when shopping on Amazon. Over 10,000 brands - from large, global brands to emerging entrepreneurs including Arduino, BMW, ChessCentral, LifeProof, OtterBox, Salvatore Ferragamo, and Veet - have already enrolled in Project Zero. Brands that are enrolled in Amazon Project Zero and already have a trademark enrolled in one of the newly launched countries will automatically be able to use Project Zero in these additional stores."

05:25 EDT Tandy Leather expects delisting determination letter from Nasdaq - Tandy Leather Factory said in a release, "The Company also announced that it will not be able to complete its financial restatement and file all outstanding periodic reports with the SEC by August 10, 2020. As previously reported, a listing panel of The Nasdaq Stock Market had granted the Company until August 10 to file those reports in order to remain listed on the Nasdaq Global Market; this date represented the full extent of the panel's discretion in this matter and, as a result, the panel is required to issue a delisting determination under the Nasdaq Listing Rules. The Company therefore expects: (1) to receive a delisting determination letter from Nasdaq notifying it that trading in the Company's shares will be suspended on Nasdaq and (2) that its common stock may remain eligible to trade on the Over-the Counter Markets' 'Pink Sheets' under the current symbol 'TLF.'" Janet Carr, CEO of Tandy Leather, commented, "As with so many other retailers, we have been severely impacted this year by the COVID-19 pandemic. We are encouraged, however, by the performance of our stores that have reopened. The reopening process is still continuing, with 97 of our 106 stores having reopened since May 22. Our reopened stores have actually performed on average above 2019 levels during this brief period, although with so many uncertainties in today's environment we cannot be sure if this will continue. If there is a silver lining to this crisis for our business, it has been that our web sales since closing our stores are up 160% versus last year. As we previously announced, this was aided by our building a centralized web fulfillment capability in our Fort Worth distribution center that now allows us to fulfill web orders worldwide from there rather than from individual stores. The interruptions from COVID-19 and the related stay-at-home orders also impacted our ability to complete our financial restatement amidst our implementation of numerous new accounting systems and controls. Because of this, despite herculean efforts from our team under unprecedented circumstances, we were not able to complete our restatement and make the required SEC filings by the August 10 deadline set by Nasdaq. This is a real disappointment to us, but we will continue to push forward to complete these filings as quickly as possible. If we are delisted as we expect, then we intend to promptly apply for re-listing on Nasdaq once the required filings have been made."